Fasenra FDA Approval History
Fasenra (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody indicated for the treatment of patients with severe eosinophilic asthma.
Development Timeline for Fasenra
|Oct 4, 2019||FDA Approves Fasenra Pen (benralizumab) Pre-Filled Auto-Injector for Self-Administration|
|Nov 14, 2017||FDA Approves Fasenra (benralizumab) for Severe Eosinophilic Asthma|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.